Cargando…
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-ca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963675/ https://www.ncbi.nlm.nih.gov/pubmed/31671775 http://dx.doi.org/10.3390/diagnostics9040166 |
_version_ | 1783488336457891840 |
---|---|
author | Furuya, Hideki Pagano, Ian Chee, Keanu Kobayashi, Takashi Wong, Regan S. Lee, Riko Rosser, Charles J. |
author_facet | Furuya, Hideki Pagano, Ian Chee, Keanu Kobayashi, Takashi Wong, Regan S. Lee, Riko Rosser, Charles J. |
author_sort | Furuya, Hideki |
collection | PubMed |
description | The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens. |
format | Online Article Text |
id | pubmed-6963675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69636752020-01-27 Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature Furuya, Hideki Pagano, Ian Chee, Keanu Kobayashi, Takashi Wong, Regan S. Lee, Riko Rosser, Charles J. Diagnostics (Basel) Article The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens. MDPI 2019-10-29 /pmc/articles/PMC6963675/ /pubmed/31671775 http://dx.doi.org/10.3390/diagnostics9040166 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Furuya, Hideki Pagano, Ian Chee, Keanu Kobayashi, Takashi Wong, Regan S. Lee, Riko Rosser, Charles J. Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title | Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_full | Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_fullStr | Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_full_unstemmed | Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_short | Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature |
title_sort | comparison of commercial elisa kits, a prototype multiplex electrochemoluminescent assay, and a multiplex bead-based immunoassay for detecting a urine-based bladder-cancer-associated diagnostic signature |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963675/ https://www.ncbi.nlm.nih.gov/pubmed/31671775 http://dx.doi.org/10.3390/diagnostics9040166 |
work_keys_str_mv | AT furuyahideki comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT paganoian comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT cheekeanu comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT kobayashitakashi comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT wongregans comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT leeriko comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature AT rossercharlesj comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature |